Metabolic Dysfunction-Associated Steatohepatitis Treatment Market Size in the 7MM was ~USD 1,700 Million in 2023, estimated DelveInsight

Metabolic Dysfunction-Associated Steatohepatitis Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Metabolic Dysfunction-Associated Steatohepatitis Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

DelveInsight's "Metabolic Dysfunction-Associated Steatohepatitis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Metabolic dysfunction-associated steatohepatitis (MASH), historical and forecasted epidemiology as well as the Metabolic dysfunction-associated steatohepatitis (MASH) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Unlock detailed insights into the Metabolic Dysfunction-Associated Steatohepatitis Market by downloading the comprehensive report from DelveInsight @ Metabolic Dysfunction-Associated Steatohepatitis Therapeutics Market [https://www.delveinsight.com/sample-request/metabolic-dysfunction-associated-steatohepatitis-mash-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Metabolic Dysfunction-Associated Steatohepatitis Market Report

* In August 2024:- Corcept Therapeutics- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH). Approximately 120 patients who are eligible for participation in the study will be randomized on Day 1 in a 2:1 ratio to 100 mg miricorilant or placebo twice weekly, for 48 weeks of treatment (Cohort A).
* In August 2024:- Regeneron Pharmaceuticals- This study is researching an investigational drug called ALN-HSD (called "study drug"). This study is focused on participants who are known to have non-alcoholic steatohepatitis (NASH). NASH is a form of non-alcoholic fatty liver disease (NAFLD). Recently, the name metabolic dysfunction associated steatohepatitis (MASH) has been introduced to replace NASH and metabolic dysfunction-associated steatotic liver disease (MASLD) to replace NAFLD. NASH occurs when fat builds up in liver cells, damaging them, and making the liver inflamed and stiff from fibrosis (scar tissue).
* The Metabolic Dysfunction-Associated Steatohepatitis Market Size in the 7MM will increase at a significant CAGR due to increasing prevalent cases of the disease and the launch of the emerging therapies.
* Based on DelveInsight's estimates, the United States had the highest number of diagnosed prevalent cases of MASH in 2023, with a total of ~9.7 million cases. Following the US, EU4 and the UK had ~3.8 million cases, while Japan had ~2.6 million cases.
* The categorization based on gender, showed that diagnosed prevalent cases in males were higher than in females in the 7MM. The male-diagnosed prevalent cases accounted for 56% of the total cases in the 7MM.
* Japan accounted for approximately 16% of the total MASH Diagnosed Prevalent Cases in the 7MM in 2023. These cases are expected to increase in the study period (2020-2034).
* The leading MASH Companies such as Corcept Therapeutics, Aligos Therapeutics, Akero Therapeutics Inc., Regeneron Pharmaceuticals, Merck Sharp & Dohme LLC, 89Bio Inc., and others.
* Promising MASH Therapies such as Efinopegdutide, Efruxifermin, Pegozafermin, ALN-HSD, ALG-055009, Miricorilant, and others.

Gain a competitive edge in the Metabolic Dysfunction-Associated Steatohepatitis Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Metabolic Dysfunction-Associated Steatohepatitis Treatment Drugs [https://www.delveinsight.com/sample-request/metabolic-dysfunction-associated-steatohepatitis-mash-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Metabolic Dysfunction-Associated Steatohepatitis Epidemiology Segmentation in the 7MM

* Metabolic Dysfunction-Associated Steatohepatitis Prevalent Cases
* Metabolic Dysfunction-Associated Steatohepatitis Diagnosed Prevalent Cases
* Metabolic Dysfunction-Associated Steatohepatitis Gender-specific Diagnosed Prevalent Cases
* Metabolic Dysfunction-Associated Steatohepatitis Severity-specific Diagnosed Prevalent Cases

Metabolic Dysfunction-Associated Steatohepatitis Market Insights

MASH is a condition in which fat builds up in liver. It is the most common chronic liver disease, affecting at least a quarter of the global adult population. MASH is the progressive form of MASLD associated with persistent liver cell injury leading to fibrosis and in a subset may progress to cirrhosis and end-stage liver disease.

Discover key developments and opportunities in the Metabolic Dysfunction-Associated Steatohepatitis Market. Click here to learn more from DelveInsight's latest report @ Metabolic Dysfunction-Associated Steatohepatitis Market Size [https://www.delveinsight.com/sample-request/metabolic-dysfunction-associated-steatohepatitis-mash-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Metabolic Dysfunction-Associated Steatohepatitis Treatment Market

MASH treatment market marks a significant milestone in medical advancements, revolutionizing the landscape of MASH treatment. REZDIFFRA has emerged as a breakthrough therapy specifically designed to target the underlying mechanisms of MASH, offering new hope to patients suffering from this debilitating condition. Clinical trials have demonstrated remarkable efficacy in reducing MASH symptoms such as inflammation and fibrosis, while also improving overall liver function and patient quality of life. This approval has provided healthcare providers with a powerful tool to combat MASH disease, filling a critical gap in treatment options and potentially reducing the burden of complications associated with advanced liver disease.

Metabolic Dysfunction-Associated Steatohepatitis Marketed Drugs

* REZDIFFRA (resmetirom): Madrigal Pharmaceuticals

REZDIFFRA is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). The emergence of the inaugural medication for MASH is a true game-changer for healthcare providers, the research community, and, most importantly, patients living with this serious liver condition. Based on the robust efficacy and safety data generated in two large Phase III MAESTRO studies, it is believed that REZDIFFRA will become the foundational therapy for patients with MASH with moderate to advanced liver fibrosis. As well as since now that the FDA has approved REZDIFFRA for MASH, pharmaceutical companies will have a better understanding of the thresholds they must meet to get future approvals.

Metabolic Dysfunction-Associated Steatohepatitis Emerging Drugs

* Pegozafermin: 89bio, Inc

Pegozafermin or BIO89-100 is a compound that specifically targets and activates a receptor known as fibroblast growth factor 21 (FGF21). FGF21 is a hormone involved in regulating glucose and lipid metabolism, and it has been shown to have potential therapeutic effects in MASH.

* Efruxifermin (EFX): Akero Therapeutics, Inc.

Efruxifermin (EFX), is Akero's lead product candidate for MASH. It is a differentiated Fc-FGF21 fusion protein engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly SC dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine, if approved, for treating MASH.

* Belapectin: Galectin Therapeutics

Belapectin a complex carbohydrate drug, targets galectin-3, a critical protein in fatty liver disease and fibrosis pathogenesis. Galectin-3 plays a major role in organ scarring diseases, including the liver, lung, kidney, heart, and vascular systems fibrotic disorders. The drug binds to galectin-3 proteins and disrupts its function.

Metabolic dysfunction-associated Steatohepatitis Market Outlook

Until mid-March, the therapeutic landscape of NASH lacked FDA, EMA, or PMDA-approved medications, relying primarily on lifestyle adjustments like diet and exercise. Supplemental interventions encompassed off-label usage of vitamin E and antidiabetic agents (e.g., pioglitazone, liraglutide) and liver transplantation in case of severe stages. Given NASH's multifaceted pathogenesis, effective treatment demands comprehensive targeting of various cellular and molecular pathways.

Download DelveInsight's Metabolic Dysfunction-Associated Steatohepatitis Market report today and stay ahead in this rapidly evolving field. @ Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials [https://www.delveinsight.com/sample-request/metabolic-dysfunction-associated-steatohepatitis-mash-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Metabolic Dysfunction-Associated Steatohepatitis Market Report

* Coverage- 7MM
* Metabolic Dysfunction-Associated Steatohepatitis Companies- Corcept Therapeutics, Aligos Therapeutics, Akero Therapeutics Inc., Regeneron Pharmaceuticals, Merck Sharp & Dohme LLC, 89Bio Inc., and others.
* MASH Therapies- Efinopegdutide, Efruxifermin, Pegozafermin, ALN-HSD, ALG-055009, Miricorilant, and others.
* Metabolic Dysfunction-Associated Steatohepatitis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Metabolic Dysfunction-Associated Steatohepatitis Unmet Needs, KOL's views, Analyst's views, Metabolic Dysfunction-Associated Steatohepatitis Market Access and Reimbursement

Download the report to understand which factors are driving Metabolic Dysfunction-Associated Steatohepatitis Market Trends @ Metabolic Dysfunction-Associated Steatohepatitis Market Trends [https://www.delveinsight.com/sample-request/metabolic-dysfunction-associated-steatohepatitis-mash-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Report Introduction

3. Country-wise MASH Market Overview at a Glance

4. MASH Market Overview by Therapeutic Class

5. Methodology of MASH Epidemiology and Market

6. Executive Summary

7. Key Events

8. Disease Background and Overview

9. Epidemiology and Patient Population

10. Patient Journey

11. Marketed Drugs

12. Emerging Drugs

13. MASH: Market Analysis

14. Key Opinion Leaders' Views

15. SWOT Analysis

16. Unmet needs

17. Market Access and Reimbursement

18. Appendix

19. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metabolic-dysfunctionassociated-steatohepatitis-treatment-market-size-in-the-7mm-was-usd-1700-million-in-2023-estimated-delveinsight]
Phone: 0650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.